Inotuzumab Ozogamicin/Rituximab Combo for Lymphoma Yields High Response Rates, Long PFS

The combination of two antibody-based targeting agents—inotuzumab ozogamicin and rituximab—demonstrated high response rates and long progression-free survival in patients with relapsed follicular lymphoma or relapsed diffuse large-B-cell lymphoma (DLBCL) in an international phase I/II multicenter, open-label study.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news